BioNTech (BNTX) 6-K: R&D Day update; Exhibit 99.1 presentation

BioNTech SE filed a Form 6‑K noting it hosted an edition of its Innovation Series R&D Day on November 11, 2025, providing an overview of strategy and clinical progress across its pipeline.

Accepted by SEC EDGAR 11/12/2025 - 07:45 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

BioNTech SE filed a Form 6‑K noting it hosted an edition of its Innovation Series R&D Day on November 11, 2025, providing an overview of strategy and clinical progress across its pipeline.

The related presentation is attached as Exhibit 99.1. The filing is signed by Chief Financial Officer Ramon Zapata‑Gomez and Chief Operating Officer Dr. Sierk Poetting.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioNTech (BNTX) file?

BioNTech filed a Form 6‑K reporting on its Innovation Series R&D Day and attaching a presentation as Exhibit 99.1.

When did BioNTech’s R&D Day occur?

The R&D Day took place on November 11, 2025.

What is included as Exhibit 99.1 in BioNTech’s 6-K?

Exhibit 99.1 is a presentation covering the company’s strategy and clinical progress overview.

Who signed the BioNTech (BNTX) 6-K?

The filing was signed by Ramon Zapata‑Gomez (Chief Financial Officer) and Dr. Sierk Poetting (Chief Operating Officer).

What period does this 6-K cover for BioNTech (BNTX)?

It is filed for the month of November 2025.

What was the purpose of BioNTech’s R&D Day?

To provide an overview of the company’s strategy and clinical progress across its pipeline.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF NOVEMBER 2025

COMMISSION FILE NUMBER 001-39081

BioNTech SE
(Translation of registrant’s name into English)

An der Goldgrube 12

D-55131 Mainz

Germany

+49 6131-9084-0
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

On November 11, 2025, BioNTech SE (the “Company”) hosted an edition of the Company’s Innovation Series R&D Day, providing an overview of the Company’s strategy and clinical progress across its pipeline. The presentation is attached hereto as Exhibit 99.1.

SIGNATURE

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioNTech SE

By:

/s/ Ramon Zapata-Gomez

By:

/s/ Dr. Sierk Poetting

Name: Ramon Zapata-Gomez

Name: Dr. Sierk Poetting

Title: Chief Financial Officer

Title: Chief Operating Officer

Date: November 12, 2025

EXHIBIT INDEX

Exhibit			Description of Exhibit
99.1			Presentation